Pink is the Color for Breast Cancer Cure with Peter Culpepper of Provectus Biopharmaceuticals

Peter Culpepper, COO and CFO of Provectus Biopharmaceuticals specializing in developing oncology and dermatology therapies joins eHealth Radio and the Pharmaceutical & Cancer Prevention Channels.

Originally used as a coal tar–derived wool dye and most commonly been used as a stain for detecting ocular conditions, PV-10 is a rose bengal formulation now in clinical trials against cancer. Now, over 230 cancer patients have been treated with PV-10, including 12 in a Phase 1 recurrent breast cancer study. The PV-10 trials are now entering Phase II and so far have shown favorable results and may prove to be an arsenal against breast cancer. Peter Culpepper is here to discuss this novel approach.

Listen to interview with host Eric Michaels and guest Peter Culpepper discuss the following:

• Please tell us more about rose bengal, what makes it a an effective cancer fighter?
• How does PV10 work against recurrent breast cancer?
• What has been the response so far?
• What other types of cancer does PV-10 treat?
• How long before PV10 will be available to patients both affected by breast and skin cancers?
• How can patients find more information about trials?

Duration: 15:42

About Provectus Biopharma
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver.

The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

About Peter R. Culpepper, CPA, MBA - Chief Financial Officer, Chief Operating Officer

Pete Culpepper has spent 20 years in the financial field working for a wide range of companies and industries in the U.S. and abroad, especially high-growth startups. His experience with for-profit companies ranges from private start-ups to publicly traded, global conglomerates. He also has worked with large non-profits and a national CPA accounting firm. He led the national operating unit of a $1 billion publicly traded telecommunications company, as well as numerous operating units in Eastern Europe for a global telecommunications company. He handled the capital reporting process for a $5 billion global construction project and the formation of systems for a division that grew $150 million in revenue in two years.

Previous employers include Neptec, Inc., a privately held optical networking component manufacturer; Metromedia Companies; and PageNet, the largest wireless messaging company in the world.

Culpepper taught undergraduate and graduate business courses for the University of Phoenix Online.

He is licensed as a Certified Public Accountant in Maryland and Tennessee.

His professional affiliations include the American Institute of Certified Public Accountants, Financial Executives International and the Financial Executives Networking Group.

Culpepper holds a master's of business administration (MBA) in finance from the University of Maryland. He earned an AAS in Accounting from the Northern Virginia Community College - Annandale, Virginia. He earned a bachelor's degree in philosophy from the College of William and Mary.

Link:
www.pvct.com

Link for clinical trials of PV-10:
http://clinicaltrials.gov/ct2/results?term=Provectus